After review of paclitaxel risks, FDA panel recommends more data - Star Tribune

After review of paclitaxel risks, FDA panel recommends more data  Star Tribune

A panel of doctors and medical experts told the Food and Drug Administration Thursday that regulators should not halt sales of paclitaxel-containing medical ...



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more